Lovenox (enoxaparin sodium) Injection, Aventis NDA 20-164/S51 6/20/03 7/6/03 Lovenox (enoxaparin sodium) Injection, Aventis NDA 20-164/S50 7/1/03 7/8/03 Lovenox (enoxaparin sodium) Injection, 300 mg/3.0, Aventis Products NDA 20-164/S43 1/23/03 1/27/03 Lovenox (enoxaparin sodium) Injection, Aventis Products NDA 20-164/S40, S45 & S6 1/9/02 2/8/02 Lovenox (enoxaparin sodium) Injection Aventis Products NDA 20-164/S036 11/17/00 11/27/00 11/27/00 Lovenox (enoxaparin sodium) Injection Aventis Products NDA 20-164/S034 9/27/00 9/29/00 Lovenox (enoxaparin sodium) Injection Aventis Products NDA 20-164/S020 8/4/00 8/4/00 Lovenox (enoxaparin sodium) Injection Rhone-Poulenc Rorer NDA 20-164/S010 1/30/98 4/24/03 Lovenox (enoxaparin sodium) Injection Rhone-Poulenc Rorer NDA 20-164/S015 12/31/98 7/3/00 Lovenox (enoxaparin sodium) Injection, Subcutaneous (SC), or OTC: Rhone-Poulenc Rorer NDA 20-164 12/31/98 1/5/99 1/5/99 Lovenox Indications:(1) the inpatient treatment of acute deep vein thrombosis with and without pulmonary embolism, when administered in conjunction with warfarin sodium, and (2) the outpatients treatment of acute deep vein thrombosis without pulmonary embolism when administered in conjunction with warfarin sodium. Lovenox (enoxaparin sodium) Injection, Aventis Pharmaceuticals